{"gene":"PML","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2008,"finding":"Arsenic trioxide induces PML SUMOylation, which triggers Lys48-linked polyubiquitination of PML and recruits RNF4 (the human orthologue of the yeast SUMO-dependent E3 ubiquitin ligase) to PML nuclear bodies, leading to proteasome-dependent degradation of PML and PML-RARα. SUMOylated PML also recruits ubiquitin and proteasomes onto PML nuclear bodies. A dominant-negative RNF4 impairs arsenic-induced differentiation, directly implicating PML-RARα catabolism in the therapeutic response.","method":"Co-immunoprecipitation, dominant-negative RNF4 expression, SUMOylation mutant analysis, ubiquitination assays, cell differentiation assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, dominant-negative rescue, SUMOylation mutant, and functional differentiation readout; widely replicated concept","pmids":["18408733"],"is_preprint":false},{"year":2008,"finding":"PML nuclear bodies coordinate PTEN localization by opposing the deubiquitylating enzyme HAUSP/USP7 through a mechanism involving the adaptor protein DAXX. PML opposes HAUSP-mediated deubiquitylation of PTEN, which is required for PTEN nuclear entry. This PML-DAXX-HAUSP network controls PTEN subcellular trafficking and is disrupted by the PML-RARα oncoprotein.","method":"Co-immunoprecipitation, knockdown/knockout studies, ubiquitylation assays, nuclear/cytoplasmic fractionation, rescue experiments with ATRA/arsenic trioxide","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, multiple orthogonal methods (fractionation, KO cells, drug rescue), single lab with rigorous controls","pmids":["18716620"],"is_preprint":false},{"year":2004,"finding":"Cytoplasmic PML isoforms are essential modulators of TGF-β signaling. Cytoplasmic PML physically interacts with Smad2/3 and SARA (Smad anchor for receptor activation) and is required for Smad2/3 phosphorylation, nuclear translocation, SARA association, and accumulation of SARA and TGF-β receptor in early endosomes. PML-null primary cells are resistant to TGF-β-dependent growth arrest, senescence, and apoptosis.","method":"Co-immunoprecipitation, Pml-null primary cell phenotyping, Smad2/3 phosphorylation assays, endosomal fractionation, cytoplasmic PML expression rescue","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, KO cells with defined phenotype, multiple orthogonal methods, published in high-impact journal","pmids":["15356634"],"is_preprint":false},{"year":2006,"finding":"PML inhibits HIF-1α synthesis under hypoxic conditions by repressing mTOR. PML physically interacts with mTOR and negatively regulates mTOR association with the small GTPase Rheb by promoting mTOR nuclear accumulation. Pml−/− cells and tumours display higher sensitivity to rapamycin and lack of PML inversely correlates with phosphorylation of ribosomal protein S6.","method":"Co-immunoprecipitation (PML-mTOR), Pml-null cell/tumour analysis, rapamycin sensitivity assays, subcellular fractionation showing mTOR nuclear accumulation, in vivo tumour models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, KO model, multiple orthogonal assays (fractionation, rapamycin sensitivity, S6 phosphorylation), in vivo validation","pmids":["16915281"],"is_preprint":false},{"year":2000,"finding":"PML physically interacts with p53 both in vitro and in vivo, co-localizes with p53 in PML nuclear bodies, and acts as a transcriptional co-activator for p53. PML-dependent p53-DNA binding activity, p53 transcriptional activation, and induction of p53 target genes (Bax, p21) upon gamma-irradiation are all impaired in Pml−/− primary cells.","method":"In vitro GST pulldown, co-immunoprecipitation in vivo, co-localization by immunofluorescence, Pml−/− cell apoptosis and transcription assays, gamma-irradiation","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro pulldown plus in vivo Co-IP, KO cells with functional transcription and apoptosis readouts, replicated across subsequent studies","pmids":["11025664"],"is_preprint":false},{"year":1998,"finding":"PML function is essential for the tumor-growth-suppressive activity of retinoic acid (RA) and for RA-induced terminal myeloid differentiation. PML is required for RA-dependent transactivation of the p21WAF1/CIP1 gene, placing PML as a critical component of the RA signaling pathway.","method":"Homologous recombination knockout of murine PML, hematopoietic differentiation assays, RA-dependent p21 transactivation assays, tumorigenesis assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined pathway placement, RA transactivation assay, in vivo tumorigenesis model","pmids":["9488655"],"is_preprint":false},{"year":2001,"finding":"PML interacts with multiple corepressors (c-Ski, N-CoR, mSin3A) and histone deacetylase 1, and this interaction is required for transcriptional repression mediated by the tumor suppressor Mad. PML-RARα, which has two corepressor-interacting sites, inhibits Mad-mediated repression, suggesting aberrant binding to corepressor complexes contributes to leukemogenesis.","method":"Co-immunoprecipitation, transcriptional reporter assays, domain mapping","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with multiple corepressors, functional transcription repression assay, single lab","pmids":["11430826"],"is_preprint":false},{"year":1998,"finding":"PML colocalizes with the non-phosphorylated fraction of the retinoblastoma protein (pRB) in nuclear bodies. Both PML and PML-RARα form complexes with the non-phosphorylated form of pRB in vivo and interact with the pRB pocket region. The B boxes and C-terminal region of PML are essential for stable complex formation. PML abolishes glucocorticoid receptor-regulated transcription activation by pRB.","method":"Co-immunoprecipitation, co-localization immunofluorescence, domain deletion mutant analysis, transcriptional reporter assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, domain mapping, functional transcription assay, single lab","pmids":["9448006"],"is_preprint":false},{"year":2002,"finding":"The DNA damage checkpoint kinase hCds1/Chk2 mediates gamma irradiation-induced apoptosis in a p53-independent manner through an ATM-hCds1/Chk2-PML pathway. PML functions downstream of ATM-hCds1/Chk2 in this pathway, defining PML's role in the p53-independent apoptotic arm of the DNA damage response.","method":"Genetic epistasis in cell lines, gamma irradiation apoptosis assays, kinase activity assays, PML-null cell studies","journal":"Nature cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis analysis with defined pathway, PML-null cells, single lab","pmids":["12402044"],"is_preprint":false},{"year":2003,"finding":"PML physically interacts with MDM2 in vivo and in vitro through two separate regions: PML residues 300–633 interact with the MDM2 acidic domain, and PML residues 1–200 (RING/B-box region) interact with the MDM2 C-terminal RING domain. MDM2 coexpression redistributes PML from nucleus to cytoplasm via interaction with the PML N-terminus and MDM2 RING domain. MDM2 inhibits PML-stimulated transcriptional activation of CBP. PML SUMOylation at K160 negatively regulates PML-MDM2 binding.","method":"Co-immunoprecipitation in vivo, GST pulldown in vitro, domain deletion mutants, subcellular fractionation, transcriptional reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro pulldown plus in vivo Co-IP, domain mapping, functional transcription assay, single lab","pmids":["12759344"],"is_preprint":false},{"year":2008,"finding":"PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated ubiquitin-proteasomal degradation. PML forms a complex containing Fbx3, Skp1, and Cullin1 (SCFFbx3 ubiquitin ligase). PML inhibits degradation of HIPK2 and p300 without inhibiting their ubiquitination, and PML/Fbx3/HIPK2 synergistically activate p53-induced transcription. PML-RARα instead promotes HIPK2 degradation.","method":"PML complex purification and mass spectrometry identification, co-immunoprecipitation, ubiquitination assays, transcriptional reporter assays, proteasome inhibitor studies","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complex purification by MS, Co-IP, functional transcription assay, single lab with multiple orthogonal methods","pmids":["18809579"],"is_preprint":false},{"year":2008,"finding":"HDAC7 promotes PML SUMOylation essential for PML nuclear body formation. HDAC7 associates with the SUMO E2 ligase Ubc9 and stimulates PML SUMOylation in vitro, acting with SUMO E3 ligase-like activity. HDAC7 knockdown reduces PML nuclear body size and number and inhibits TNF-α-induced PML SUMOylation in HUVECs.","method":"HDAC7 knockdown (siRNA), in vitro SUMOylation assay, co-immunoprecipitation, immunofluorescence of PML bodies","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro SUMOylation assay, Co-IP, KD with phenotypic readout, single lab","pmids":["18625722"],"is_preprint":false},{"year":2000,"finding":"PML is critical for proper localization of all other ND10/PML-body-associated proteins. Introducing PML into PML−/− cells recruits ND10-associated proteins (including Daxx, Sp100) into de novo formed ND10 bodies. Increased SUMO-1 modification of PML segregates Daxx from condensed chromatin to ND10, demonstrating that SUMO-1 modification of PML controls recruitment of partner proteins.","method":"Transient transfection in PML−/− cells, cell fusion experiments, immunofluorescence, SUMO-1 overexpression","journal":"Journal of structural biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PML reconstitution in null cells, multiple partner proteins assessed, single lab","pmids":["10806078"],"is_preprint":false},{"year":1999,"finding":"PML and Sp100 are conjugated to SUMO-1 during interphase but become de-conjugated during mitosis. A mitosis-specific PML isoform of distinct electrophoretic mobility appears that is stabilized by phosphatase inhibitors, indicating phosphorylation is an important modifier of PML during the cell cycle. Treatment with phosphatase inhibitors in interphase cells induces PML isoforms resembling the mitotic form and causes structural changes in ND10.","method":"Cell cycle synchronization, immunoblotting for SUMO-1-conjugated PML, phosphatase inhibitor treatment, immunofluorescence of PML bodies","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical cell-cycle analysis, pharmacological modulation, single lab with multiple conditions","pmids":["10574707"],"is_preprint":false},{"year":2000,"finding":"PML nuclear body core is a dense, protein-based structure (~250 nm diameter) that does not contain detectable nucleic acid (no RNA or chromatin). Newly synthesized RNA is associated with the periphery of PML nuclear bodies, not within the protein core. These bodies are not sites of transcription.","method":"Electron spectroscopic imaging (ESI) analytical transmission electron microscopy, 5-bromouridine RNA labeling","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative structural method (ESI-TEM) with rigorous compositional analysis, directly falsified prior RNA-accumulation model","pmids":["10648561"],"is_preprint":false},{"year":2008,"finding":"PML and YAP physically interact through PML's PVPVY motif and YAP's WW domain. PML-mediated SUMOylation stabilizes YAP. PML is a direct transcriptional target of p73/YAP, forming a proapoptotic autoregulatory feedback loop. Akt/PKB kinase negatively controls PML transcriptional activation by p73/YAP.","method":"Co-immunoprecipitation, domain mutant analysis (PVPVY/WW), SUMOylation assays, transcriptional reporter assays, Akt inhibitor studies","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping, SUMOylation assay, functional transcription readout, single lab","pmids":["19111660"],"is_preprint":false},{"year":2002,"finding":"PML forms a complex with STAT3 through its B-box and C-terminal regions in vitro and in vivo, inhibiting STAT3 DNA-binding activity. PML-RARα dissociates PML from STAT3 and restores STAT3 activity. In cells dependent on gp130/STAT3-mediated growth, PML abrogates proliferation while PML-RARα enhances it.","method":"Co-immunoprecipitation, GST pulldown, luciferase transcription assays, EMSA for STAT3 DNA binding, Ba/F3 cell growth assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro pulldown, in vivo Co-IP, EMSA, functional cell growth assay, single lab","pmids":["12506013"],"is_preprint":false},{"year":2003,"finding":"ZIP kinase (ZIPK) is present in PML nuclear bodies (PODs) and colocalizes with and binds to proapoptotic protein Daxx. Arsenic trioxide and IFN-γ increase the association of ZIPK with PODs. Kinase-inactive ZIPK has diffuse nuclear localization and prevents Daxx association with PODs, indicating ZIPK recruits Daxx via its catalytic activity. ZIPK also binds and phosphorylates Par-4; siRNA knockdown of ZIPK, Daxx, or Par-4 decreases caspase activation and apoptosis induced by arsenic/IFN-γ.","method":"Co-immunoprecipitation, immunofluorescence co-localization, kinase-dead mutant analysis, siRNA knockdown, caspase activity assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, kinase-dead mutant, siRNA KD with functional apoptosis readout, single lab","pmids":["12917339"],"is_preprint":false},{"year":2010,"finding":"PML isoforms I and II partially restore restriction of ICP0-null mutant HSV-1 replication in PML-depleted cells. The antiviral activity of PML isoform I requires its SUMO modification, its SUMO interaction motif (SIM), and each element of its TRIM domain. Deletion of the SIM motif from PML isoform I increases colocalization with other major ND10 components.","method":"Individual PML isoform expression in PML-depleted cells, viral plaque assays, SUMO modification site mutagenesis, SIM deletion mutants, immunofluorescence","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific rescue, domain mutants, functional viral replication assay, single lab","pmids":["21172801"],"is_preprint":false},{"year":2010,"finding":"SIRT1 stabilizes PML protein and stimulates PML SUMOylation in vitro and in vivo in a deacetylase-independent manner. SIRT1 knockdown reduces PML protein levels, PML nuclear body size and number. SIRT1 absence reduces the apoptotic response to VSV infection and favors PML-sensitive virus replication.","method":"In vitro SUMOylation assay, SIRT1 knockdown (shRNA/siRNA), SIRT1 knockout MEFs, immunofluorescence of PML bodies, viral replication assay","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro SUMOylation assay, KO cells, KD with functional readouts, single lab","pmids":["20577263"],"is_preprint":false},{"year":2011,"finding":"PML induces a permanent cell cycle exit and activates p53 and senescence by recruiting E2F transcription factors (bound to their promoters) and Rb proteins to PML nuclear bodies enriched in heterochromatin proteins and protein phosphatase 1α. Blocking Rb family function or adding back E2Fs rescues E2F-dependent gene expression and proliferation, inhibiting the senescent phenotype.","method":"Immunoprecipitation, immunofluorescence, chromatin immunoprecipitation (ChIP), Rb functional blockade, E2F rescue experiments, cell proliferation assays","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, Co-IP, rescue experiments, multiple orthogonal methods, single lab","pmids":["21205865"],"is_preprint":false},{"year":2012,"finding":"PML protein physically interacts with PER2 and is expressed in a circadian manner in the suprachiasmatic nucleus (SCN). Loss of PML disrupts expression of clock regulators (Per2, Per1, Cry1, Bmal1, Npas2), and in Pml−/− cells PER2 distribution is primarily perinuclear/cytoplasmic rather than nuclear. PML is acetylated at K487, and its deacetylation by SIRT1 promotes PML control of PER2 nuclear localization. In Pml−/− mice, circadian period shows reduced precision and stability.","method":"Co-immunoprecipitation (PML-PER2), Pml−/− mouse circadian phenotyping, immunofluorescence/subcellular fractionation of PER2, acetylation site mutagenesis (K487), SIRT1 deacetylation assay","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, KO mouse phenotype, acetylation site mutagenesis, multiple orthogonal methods, single lab","pmids":["22274616"],"is_preprint":false},{"year":2015,"finding":"PML/TRIM19 inhibits retroviral (HIV-1) reverse transcription indirectly through stabilization of Daxx. In the presence of PML, cytoplasmic Daxx is found in the vicinity of incoming HIV-1 capsids and inhibits reverse transcription. HIV-1 infection triggers formation of PML cytoplasmic bodies within 30 min, peaking at ~2 h post-infection. PML re-localization is blocked by reverse-transcription inhibitors.","method":"PML knockdown (siRNA), quantitative RT-PCR of HIV cDNA intermediates, immunofluorescence of PML cytoplasmic bodies, reverse-transcription inhibitor treatment, Daxx depletion experiments","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with functional viral replication assay, imaging, pharmacological inhibition, single lab","pmids":["26566030"],"is_preprint":false},{"year":2011,"finding":"PML is functionally connected to the homologous recombination (HR) repair machinery. PML depletion abrogates Rad51, Mre11, BRCA1, and RPA foci following DNA damage. PML associates with Rad51 following LT expression or external DNA damage. PML-depleted cells fail to generate ssDNA foci or activate Chk1 upon gamma-irradiation, indicating PML is required for DSB processing. PML is also required for HR-mediated repair as measured by a direct HR assay.","method":"PML knockdown (siRNA), immunofluorescence for DNA repair foci, Co-immunoprecipitation (PML-Rad51), HR reporter assay, BrdU incorporation (ssDNA detection), Chk1 phosphorylation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, multiple foci assays, functional HR assay, single lab with multiple orthogonal methods","pmids":["21998700"],"is_preprint":false},{"year":2018,"finding":"PML acts as a reactive oxygen species (ROS) sensor. Pml−/− cells accumulate ROS, whereas PML expression decreases ROS levels. Pml−/− animals fail to properly activate oxidative stress-responsive p53 targets, while the NRF2 response is amplified. In an oxidative stress-prone background, Pml−/− animals display a longevity phenotype reflecting decreased basal p53 activation. PML couples ROS sensing to p53 responses through NB biogenesis.","method":"Pml−/− mouse models, ROS measurement assays, p53 target gene induction assays, acetaminophen hepatotoxicity model, fasting-induced steatosis model, glutathione depletion experiment","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse model with multiple in vivo stress paradigms, molecular target gene readouts, single lab","pmids":["28931625"],"is_preprint":false},{"year":2019,"finding":"PML RBCC domain undergoes sequential oligomerization (monomer → dimer → tetramer → N-mer) mediated by B1-box interfaces (W157, F158, SD1). Crystal structure of PML B1-box at 2.0 Å resolution and SAXS characterization define these interfaces. B1 interface mutations abolish PML SUMOylation and nuclear body biogenesis in HeLaPml−/− cells. In vivo, PML-RARα F158E mutation (disrupting B1 oligomerization) precludes leukemogenesis in transgenic mice.","method":"Crystal structure (2.0 Å), SAXS, gel filtration, ultracentrifugation, B1 interface mutagenesis, PML nuclear body reconstitution in HeLaPml−/− cells, transgenic mouse leukemogenesis model, single-cell RNA sequencing","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mutagenesis, SAXS, in vitro biochemistry, in vivo transgenic mouse validation, multiple orthogonal methods","pmids":["31439836"],"is_preprint":false},{"year":2017,"finding":"WDR4-containing CRL4WDR4 ubiquitin ligase mediates PML ubiquitination and degradation. This pathway is hyperactivated in lung cancer. The WDR4/PML axis induces CD73, uPAR, and SAA2 to elicit paracrine effects promoting migration, invasion, and metastasis. In vivo, this axis elevates intratumoral Tregs and M2-like macrophages and reduces CD8+ T cells.","method":"Co-immunoprecipitation, ubiquitination assays, WDR4 knockdown/overexpression, xenograft and genetically engineered mouse models, CD73 blockade rescue","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, in vivo mouse models, rescue experiment, single lab","pmids":["28691927"],"is_preprint":false},{"year":2010,"finding":"Overexpression of nuclear PML isoforms (I–VI) in human cells increases IFN-γ-induced STAT1 phosphorylation, enhances STAT1 DNA binding, activates IFN-stimulated genes, and increases their protein products. These effects require PML nuclear localization, PML SUMOylation, and the RING finger domain. Conversely, PML knockdown or PML−/− MEFs show decreased IFN-γ-induced STAT1 phosphorylation and STAT1 DNA-binding activity.","method":"PML isoform overexpression, PML siRNA knockdown, PML−/− MEF analysis, STAT1 phosphorylation assays, EMSA for STAT1 DNA binding, ISG expression assays, SUMOylation mutant analysis","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific effects, KO cells, domain mutants, EMSA, single lab with multiple methods","pmids":["21115099"],"is_preprint":false},{"year":2018,"finding":"PML physically binds TET2 via its C-terminal domain and recruits TET2 to PML-positive nuclear bodies, promoting 5-hydroxymethylcytosine (5hmC) formation in response to chemotherapeutic agents. PML-RARA (missing the PML C-terminal domain) disrupts this interaction. Knockout of PML abolishes doxorubicin-promoted DNA modification.","method":"SILAC immunoprecipitation-mass spectrometry, co-immunoprecipitation, PML KO cells, 5hmC quantification, domain-deletion mutant analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-based interactome identification, Co-IP confirmation, KO cells with functional 5hmC readout, single lab","pmids":["29735542"],"is_preprint":false},{"year":2017,"finding":"PML undergoes oxidation-mediated multimerization and de-SUMOylation in response to Listeria monocytogenes infection via the pore-forming toxin listeriolysin O (LLO). This de-SUMOylation is sensed as a danger signal leading to restriction of bacterial intracellular multiplication. Specific induction of PML de-SUMOylation phenocopies the LLO-induced antibacterial response.","method":"PML oxidation/multimerization assays, SUMOylation immunoblotting, LLO-deficient Listeria mutant comparison, PML de-SUMOylation induction, transcriptomic and proteomic microarrays, Pml−/− cell infection assays","journal":"mBio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical modification assays, bacterial mutant controls, pharmacological de-SUMOylation, KO cells, single lab","pmids":["28074026"],"is_preprint":false},{"year":2018,"finding":"IFN-α treatment increases global cellular SUMOylation in a PML-dependent manner. This effect is orchestrated specifically by PML isoforms III and IV. IFN-α induces PML-dependent transfer of the SUMO E2 enzyme UBC9 to the nuclear matrix where it colocalizes with PML in nuclear bodies and enhances global SUMOylation.","method":"Large-scale SUMO proteomics (mass spectrometry), individual PML isoform expression in PML-negative cells, UBC9 nuclear matrix fractionation, immunofluorescence co-localization","journal":"Molecular & cellular proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics, isoform-specific rescue, fractionation, Co-localization, single lab","pmids":["29535160"],"is_preprint":false},{"year":2011,"finding":"PML physically interacts with TBX2 (a T-box transcription factor) and negatively regulates TBX2 expression. Recruitment of PML to the TBX2 promoter depends on a functional p130/E2F4 repressor complex, implementing transcriptionally inactive chromatin at the TBX2 promoter. TBX2 depletion triggers PML pro-senescence functions; elevated TBX2 antagonizes PML pro-senescence function through direct protein-protein interaction.","method":"ChIP, gene expression profiling, promoter reporter assay, co-immunoprecipitation, TBX2 knockdown and overexpression, senescence assays","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, Co-IP, functional senescence assays, multiple methods, single lab","pmids":["22002537"],"is_preprint":false},{"year":1991,"finding":"The MYL/PML-RARα fusion protein encoded by the t(15;17) translocation of APL includes RAR-α DNA- and retinoid-binding regions but lacks the RAR-α N-terminal A/B transactivation domain. The fusion protein acts as a retinoid-inducible transcription factor with ligand-independent repressor and ligand-dependent activator functions, and has ~10-fold greater affinity for RA than RARα alone.","method":"cDNA cloning and sequencing, retinoid-binding assays, transactivation reporter assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro binding assay, transactivation assay, molecular characterization, single lab","pmids":["1650447"],"is_preprint":false},{"year":1998,"finding":"PML overexpression induces rapid cell death independent of de novo transcription, caspase-3 activation, or cell cycling. BAX and p27KIP1 are novel PML nuclear body-associated proteins recruited by PML. Arsenic enhances targeting of PML, BAX, and p27KIP1 to nuclear bodies and synergizes with PML and IFN to induce cell death. Caspase inhibitors (zVAD) accelerate PML-induced death.","method":"PML overexpression in multiple cell lines, immunofluorescence for BAX/p27KIP1 localization at NBs, caspase inhibitor treatment, arsenic trioxide treatment, cell death assays","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence, pharmacological rescue, single lab","pmids":["9806544"],"is_preprint":false},{"year":2022,"finding":"PML/RARα is neddylated in its RARα moiety; this neddylation enhances DNA-binding ability of PML/RARα and impedes phase separation of the PML moiety, disrupting PML nuclear body assembly. Deneddylation of PML/RARα restores its phase separation to reconstruct functional PML nuclear bodies and activates RARα signaling, suppressing leukemogenesis. Pharmacological neddylation inhibition by MLN4924 eradicates APL cells in vitro and in vivo.","method":"Neddylation site identification, DNA-binding assays, phase separation assays, PML NB reconstitution, MLN4924 treatment in vitro and in APL mouse models","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — neddylation assays, phase separation assay, in vivo APL model, pharmacological rescue, single lab","pmids":["35194189"],"is_preprint":false},{"year":2008,"finding":"UBE1L (ubiquitin-activating enzyme E1-like) induces ISG15 conjugation (ISG15ylation) of the PML domain of PML/RARα, causing its repression and degradation via the proteasome. This is mechanistically distinct from RA-induced RARα-domain targeting. USP18/UBP43 (the ISG15 deconjugase) opposes UBE1L-dependent (but not RA-dependent) PML/RARα degradation.","method":"Domain-specific transfection assays, ISG15ylation assays, proteasome inhibitor studies, USP18 rescue experiments","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-specific ISG15ylation assay, proteasome inhibitor, specific deconjugase rescue, single lab","pmids":["18413804"],"is_preprint":false}],"current_model":"PML is the essential scaffold of PML nuclear bodies (NBs) — protein-based subnuclear organelles assembled through sequential B1-box-mediated oligomerization — where it functions as a SUMO E3 ligase platform that concentrates partner proteins (including p53, pRB, STAT3, Smad2/3, TET2, Daxx, Rad51, HIPK2, p300, and many others) to regulate their post-translational modification (SUMOylation, acetylation, ubiquitination), stability, localization, and activity; PML also acts in the cytoplasm as a TGF-β signal transducer by scaffolding Smad2/3-SARA complexes at early endosomes, suppresses mTOR by promoting its nuclear sequestration away from Rheb, senses reactive oxygen species to couple oxidative stress to p53 activation, and undergoes SUMO-triggered RNF4-mediated polyubiquitination and proteasomal degradation in response to arsenic trioxide, which underpins the therapeutic clearance of PML-RARα in acute promyelocytic leukemia."},"narrative":{"mechanistic_narrative":"PML is the essential scaffold of PML nuclear bodies (ND10), subnuclear protein-based structures that concentrate partner proteins to control their post-translational modification, stability, and localization; introducing PML into PML-null cells recruits ND10-associated proteins such as Daxx and Sp100, and increased SUMO-1 modification of PML drives this recruitment [PMID:10806078]. Body biogenesis depends on sequential B1-box-mediated oligomerization of the PML RBCC domain (monomer→dimer→tetramer→N-mer), and B1-interface mutations abolish PML SUMOylation and nuclear-body formation [PMID:31439836]; the body core is a dense protein structure that excludes nucleic acid and is not a site of transcription [PMID:10648561]. PML SUMOylation is the central regulatory switch governing partner recruitment, and is stimulated by accessory factors including HDAC7 and SIRT1, both of which control PML body size and number [PMID:18625722, PMID:20577263]. Through these bodies PML potentiates p53 function, acting as a p53 transcriptional co-activator required for p53 target induction after gamma-irradiation [PMID:11025664] and coupling reactive oxygen species sensing to p53 activation, with Pml-null animals failing to mount oxidative-stress-responsive p53 programs [PMID:28931625]; it likewise enforces senescence by sequestering E2F/Rb complexes at heterochromatin-enriched bodies [PMID:21205865] and contributes to homologous recombination repair by enabling Rad51, Mre11, BRCA1, and RPA focus formation and DSB processing [PMID:21998700]. PML also functions outside the body and nucleus: cytoplasmic PML scaffolds Smad2/3-SARA complexes at early endosomes to transduce TGF-β signaling [PMID:15356634], represses mTOR by promoting its nuclear sequestration away from Rheb [PMID:16915281], and supports antiviral and antibacterial restriction through Daxx stabilization and oxidation-triggered de-SUMOylation [PMID:26566030, PMID:28074026]. In acute promyelocytic leukemia the t(15;17) PML-RARα fusion retains RARα DNA- and retinoid-binding regions while losing the RARα transactivation domain [PMID:1650447]; arsenic trioxide induces PML SUMOylation that triggers RNF4-dependent K48 polyubiquitination and proteasomal degradation of PML and PML-RARα, underpinning the therapeutic response, and PML function is required for retinoic-acid-induced differentiation and tumor suppression [PMID:18408733, PMID:9488655].","teleology":[{"year":1991,"claim":"Defining the molecular nature of the APL fusion oncoprotein established that PML-RARα is an aberrant retinoid receptor, framing PML's relevance to leukemia.","evidence":"cDNA cloning, retinoid-binding and transactivation assays of the t(15;17) fusion","pmids":["1650447"],"confidence":"Medium","gaps":["Did not address normal PML function","No structural mechanism for how the fusion subverts PML bodies"]},{"year":1998,"claim":"Knockout of PML placed it as an essential effector of retinoic-acid-induced differentiation and tumor suppression, establishing physiological function beyond the fusion.","evidence":"Murine PML knockout, myeloid differentiation, RA-dependent p21 transactivation and tumorigenesis assays","pmids":["9488655"],"confidence":"High","gaps":["Mechanism by which PML enables RA transactivation not resolved","Did not establish the body-level mechanism"]},{"year":2000,"claim":"Reconstitution in PML-null cells showed PML is the organizer that recruits all other ND10 components, defining its scaffold role and the SUMO-dependence of partner recruitment.","evidence":"Transfection/cell-fusion in PML-/- cells, immunofluorescence, SUMO-1 overexpression","pmids":["10806078"],"confidence":"Medium","gaps":["SUMO E3 machinery for PML not identified here","Quantitative oligomerization mechanism unknown"]},{"year":2000,"claim":"Structural imaging established that PML body cores are protein-based and nucleic-acid-free, falsifying the prior model that bodies are transcription/RNA-accumulation sites.","evidence":"Electron spectroscopic imaging and 5-bromouridine RNA labeling","pmids":["10648561"],"confidence":"High","gaps":["Did not define the molecular assembly principle of the core","Function of peripheral RNA association left open"]},{"year":2000,"claim":"Demonstrating that PML co-activates p53 connected the bodies to a tumor-suppressor transcriptional program engaged after DNA damage.","evidence":"GST pulldown, in vivo Co-IP, PML-/- cell transcription and apoptosis assays after gamma-irradiation","pmids":["11025664"],"confidence":"High","gaps":["Whether co-activation requires SUMO-dependent recruitment not shown","Direct enzymatic role on p53 not defined"]},{"year":2002,"claim":"PML was placed in a p53-independent DNA-damage apoptotic arm and shown to restrain STAT3, broadening its role to checkpoint signaling and cytokine response.","evidence":"ATM-Chk2 epistasis with PML-null cells; PML-STAT3 Co-IP, EMSA, Ba/F3 growth assays","pmids":["12402044","12506013"],"confidence":"Medium","gaps":["Direct biochemical link between Chk2 and PML not resolved","How PML body localization gates STAT3 inhibition unclear"]},{"year":2004,"claim":"Identification of a cytoplasmic PML pool scaffolding Smad2/3-SARA at endosomes established a non-nuclear signal-transduction function in TGF-β responses.","evidence":"Co-IP, Pml-null primary cell phenotyping, endosomal fractionation, cytoplasmic PML rescue","pmids":["15356634"],"confidence":"High","gaps":["Determinants of nuclear vs cytoplasmic PML partitioning not defined","Structural basis of Smad/SARA scaffolding unknown"]},{"year":2006,"claim":"PML was shown to suppress mTOR by promoting its nuclear sequestration away from Rheb, linking the bodies to translational/hypoxic control.","evidence":"PML-mTOR Co-IP, Pml-null tumors, rapamycin sensitivity and S6 phosphorylation, in vivo tumor models","pmids":["16915281"],"confidence":"High","gaps":["How PML physically retains mTOR in the nucleus not detailed","Relationship to NB SUMOylation switch unclear"]},{"year":2008,"claim":"Arsenic-induced PML SUMOylation was shown to recruit RNF4 and drive K48 polyubiquitination and proteasomal degradation of PML/PML-RARα, providing the molecular basis for APL therapy.","evidence":"Reciprocal Co-IP, dominant-negative RNF4, SUMO-site mutants, ubiquitination and differentiation assays","pmids":["18408733"],"confidence":"High","gaps":["Stoichiometry/site specificity of the SUMO-ubiquitin handoff not fully mapped"]},{"year":2008,"claim":"Multiple 2008 studies expanded PML's modification-control logic: it gates PTEN nuclear trafficking via DAXX/HAUSP, protects HIPK2/p300 from SCFFbx3 degradation, and depends on HDAC7 for body-forming SUMOylation.","evidence":"Co-IP, ubiquitylation assays, fractionation, MS-based complex purification, in vitro SUMOylation, knockdowns","pmids":["18716620","18809579","18625722"],"confidence":"Medium","gaps":["Each interaction characterized in single labs","How a single scaffold coordinates so many distinct modification outcomes unresolved"]},{"year":2011,"claim":"PML was integrated into homologous-recombination repair and senescence enforcement, showing the bodies physically organize repair factors and E2F/Rb-driven cell-cycle exit.","evidence":"PML knockdown with Rad51/Mre11/BRCA1/RPA foci and HR reporter assays; ChIP/Co-IP of E2F-Rb recruitment with senescence rescue","pmids":["21998700","21205865"],"confidence":"Medium","gaps":["Whether PML acts directly on repair complexes or via sequestration unclear","Causal order of body assembly vs senescence entry not resolved"]},{"year":2019,"claim":"Structural and mutagenesis work defined the B1-box oligomerization interfaces required for SUMOylation and body biogenesis, and showed disrupting them blocks PML-RARα leukemogenesis in vivo.","evidence":"2.0 Å crystal structure, SAXS, B1-interface mutagenesis, NB reconstitution in HeLaPML-/-, transgenic mouse model","pmids":["31439836"],"confidence":"High","gaps":["How oligomerization couples to the SUMO E2/E3 reaction mechanistically not fully defined"]},{"year":2022,"claim":"Neddylation of the RARα moiety was shown to impede PML phase separation and body assembly, with deneddylation (MLN4924) restoring functional bodies and suppressing leukemia, adding a phase-behavior layer to APL biology.","evidence":"Neddylation site mapping, phase separation and DNA-binding assays, NB reconstitution, MLN4924 in APL mouse models","pmids":["35194189"],"confidence":"Medium","gaps":["In-cell evidence for endogenous PML phase separation limited","Single-lab characterization"]},{"year":null,"claim":"How the many PML isoforms and the SUMOylation/oligomerization/phase-separation switches are integrated to select among the protein's diverse outputs (p53 co-activation, mTOR suppression, TGF-β transduction, repair, immune restriction) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking isoform identity to specific functional output","Mechanism that partitions nuclear vs cytoplasmic PML pools undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,11,30]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,16,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,10,1]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[24,29]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12,14,25]},{"term_id":"GO:0043226","term_label":"organelle","supporting_discovery_ids":[12,14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,22]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,32,34]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,10,30]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18,22,27,29]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[23,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,33]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[24,20]}],"complexes":["PML nuclear body (ND10)","SCF(Fbx3) ubiquitin ligase complex","Smad2/3-SARA endosomal complex"],"partners":["P53","DAXX","RNF4","MTOR","SMAD2/3","RAD51","TET2","STAT3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29590","full_name":"Protein PML","aliases":["E3 SUMO-protein ligase PML","Promyelocytic leukemia protein","RING finger protein 71","RING-type E3 SUMO transferase PML","Tripartite motif-containing protein 19","TRIM19"],"length_aa":882,"mass_kda":97.6,"function":"Exhibits antiviral activity against both DNA and RNA viruses. The antiviral activity can involve one or several isoform(s) and can be enhanced by the permanent PML-NB-associated protein DAXX or by the recruitment of p53/TP53 within these structures. Isoform PML-4 restricts varicella zoster virus (VZV) via sequestration of virion capsids in PML-NBs thereby preventing their nuclear egress and inhibiting formation of infectious virus particles. The sumoylated isoform PML-4 restricts rabies virus by inhibiting viral mRNA and protein synthesis. The cytoplasmic isoform PML-14 can restrict herpes simplex virus-1 (HHV-1) replication by sequestering the viral E3 ubiquitin-protein ligase ICP0 in the cytoplasm. Isoform PML-6 shows restriction activity towards human cytomegalovirus (HHV-5) and influenza A virus strains PR8(H1N1) and ST364(H3N2). Sumoylated isoform PML-4 and isoform PML-12 show antiviral activity against encephalomyocarditis virus (EMCV) by promoting nuclear sequestration of viral polymerase (P3D-POL) within PML NBs. Isoform PML-3 exhibits antiviral activity against poliovirus by inducing apoptosis in infected cells through the recruitment and the activation of p53/TP53 in the PML-NBs. Isoform PML-3 represses human foamy virus (HFV) transcription by complexing the HFV transactivator, bel1/tas, preventing its binding to viral DNA. PML may positively regulate infectious hepatitis C viral (HCV) production and isoform PML-2 may enhance adenovirus transcription. Functions as an E3 SUMO-protein ligase that sumoylates (HHV-5) immediate early protein IE1, thereby participating in the antiviral response (PubMed:20972456, PubMed:28250117). Isoforms PML-3 and PML-6 display the highest levels of sumoylation activity (PubMed:20972456, PubMed:28250117)","subcellular_location":"Nucleus; Nucleus, nucleoplasm; Cytoplasm; Nucleus, PML body; Nucleus, nucleolus; Endoplasmic reticulum membrane; Early endosome membrane","url":"https://www.uniprot.org/uniprotkb/P29590/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PML","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CALM1","stoichiometry":0.2},{"gene":"CALM2","stoichiometry":0.2},{"gene":"CALM3","stoichiometry":0.2},{"gene":"LDHB","stoichiometry":0.2},{"gene":"MIF","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PML","total_profiled":1310},"omim":[{"mim_id":"621303","title":"ARKADIA/RNF111 N-TERMINAL-LIKE PKA SIGNALING REGULATOR 2N; ARK2N","url":"https://www.omim.org/entry/621303"},{"mim_id":"619230","title":"SIN3A-ASSOCIATED PROTEIN, 25-KD; SAP25","url":"https://www.omim.org/entry/619230"},{"mim_id":"618610","title":"HOMEOBOX-CONTAINING PROTEIN 1; HMBOX1","url":"https://www.omim.org/entry/618610"},{"mim_id":"617962","title":"ZINC FINGER PROTEIN 827; ZNF827","url":"https://www.omim.org/entry/617962"},{"mim_id":"617747","title":"NUCLEAR BODY PROTEIN SP140-LIKE; SP140L","url":"https://www.omim.org/entry/617747"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nuclear bodies","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PML"},"hgnc":{"alias_symbol":["MYL","TRIM19","RNF71"],"prev_symbol":[]},"alphafold":{"accession":"P29590","domains":[{"cath_id":"3.30.40.10","chopping":"50-184","consensus_level":"medium","plddt":85.7245,"start":50,"end":184},{"cath_id":"-","chopping":"232-361","consensus_level":"medium","plddt":94.1596,"start":232,"end":361},{"cath_id":"3.30.420.10","chopping":"609-771","consensus_level":"high","plddt":86.3471,"start":609,"end":771}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29590","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29590-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29590-F1-predicted_aligned_error_v6.png","plddt_mean":70.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PML","jax_strain_url":"https://www.jax.org/strain/search?query=PML"},"sequence":{"accession":"P29590","fasta_url":"https://rest.uniprot.org/uniprotkb/P29590.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29590/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29590"}},"corpus_meta":[{"pmid":"18408733","id":"PMC_18408733","title":"Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.","date":"2008","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18408733","citation_count":611,"is_preprint":false},{"pmid":"10806494","id":"PMC_10806494","title":"The transcriptional role of PML and the nuclear body.","date":"2000","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10806494","citation_count":476,"is_preprint":false},{"pmid":"20452955","id":"PMC_20452955","title":"PML nuclear bodies.","date":"2010","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20452955","citation_count":459,"is_preprint":false},{"pmid":"18716620","id":"PMC_18716620","title":"The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/18716620","citation_count":455,"is_preprint":false},{"pmid":"11832207","id":"PMC_11832207","title":"The role of PML in tumor suppression.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11832207","citation_count":453,"is_preprint":false},{"pmid":"9488655","id":"PMC_9488655","title":"Role of PML in cell growth and the retinoic acid pathway.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9488655","citation_count":439,"is_preprint":false},{"pmid":"11025664","id":"PMC_11025664","title":"The function of PML in p53-dependent apoptosis.","date":"2000","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11025664","citation_count":396,"is_preprint":false},{"pmid":"11704850","id":"PMC_11704850","title":"PML protein isoforms and the RBCC/TRIM motif.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11704850","citation_count":382,"is_preprint":false},{"pmid":"17343971","id":"PMC_17343971","title":"PML and PML nuclear bodies: implications in antiviral defence.","date":"2007","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/17343971","citation_count":368,"is_preprint":false},{"pmid":"15351967","id":"PMC_15351967","title":"PML nuclear bodies: dynamic sensors of DNA damage and cellular stress.","date":"2004","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15351967","citation_count":334,"is_preprint":false},{"pmid":"1650447","id":"PMC_1650447","title":"Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties.","date":"1991","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1650447","citation_count":329,"is_preprint":false},{"pmid":"9806544","id":"PMC_9806544","title":"PML induces a novel caspase-independent death process.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9806544","citation_count":322,"is_preprint":false},{"pmid":"16915281","id":"PMC_16915281","title":"PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16915281","citation_count":320,"is_preprint":false},{"pmid":"15356634","id":"PMC_15356634","title":"Cytoplasmic PML function in TGF-beta signalling.","date":"2004","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15356634","citation_count":256,"is_preprint":false},{"pmid":"10806078","id":"PMC_10806078","title":"Review: properties and assembly mechanisms of ND10, PML bodies, or PODs.","date":"2000","source":"Journal of structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/10806078","citation_count":238,"is_preprint":false},{"pmid":"10648561","id":"PMC_10648561","title":"Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA.","date":"2000","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10648561","citation_count":223,"is_preprint":false},{"pmid":"19111660","id":"PMC_19111660","title":"PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19111660","citation_count":221,"is_preprint":false},{"pmid":"11704855","id":"PMC_11704855","title":"DNA viruses and viral proteins that interact with PML nuclear bodies.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11704855","citation_count":217,"is_preprint":false},{"pmid":"8609713","id":"PMC_8609713","title":"Induction of the PML protein by interferons in normal and APL cells.","date":"1995","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8609713","citation_count":196,"is_preprint":false},{"pmid":"12402044","id":"PMC_12402044","title":"PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.","date":"2002","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12402044","citation_count":195,"is_preprint":false},{"pmid":"29723661","id":"PMC_29723661","title":"PML nuclear bodies: from architecture to function.","date":"2018","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29723661","citation_count":185,"is_preprint":false},{"pmid":"10574707","id":"PMC_10574707","title":"Cell cycle regulation of PML modification and ND10 composition.","date":"1999","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10574707","citation_count":164,"is_preprint":false},{"pmid":"14663483","id":"PMC_14663483","title":"Role of PML and the PML-nuclear body in the control of programmed cell death.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14663483","citation_count":148,"is_preprint":false},{"pmid":"27053550","id":"PMC_27053550","title":"Emerging Role of PML Nuclear Bodies in Innate Immune Signaling.","date":"2016","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/27053550","citation_count":144,"is_preprint":false},{"pmid":"15077145","id":"PMC_15077145","title":"PML nuclear bodies and apoptosis.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15077145","citation_count":143,"is_preprint":false},{"pmid":"9448006","id":"PMC_9448006","title":"The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9448006","citation_count":139,"is_preprint":false},{"pmid":"23734343","id":"PMC_23734343","title":"Differential Roles of PML Isoforms.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23734343","citation_count":133,"is_preprint":false},{"pmid":"21205865","id":"PMC_21205865","title":"Regulation of E2Fs and senescence by PML nuclear bodies.","date":"2011","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/21205865","citation_count":133,"is_preprint":false},{"pmid":"18931695","id":"PMC_18931695","title":"Regulation of apoptosis by PML and the PML-NBs.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18931695","citation_count":127,"is_preprint":false},{"pmid":"11430826","id":"PMC_11430826","title":"Role of PML and PML-RARalpha in Mad-mediated transcriptional repression.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11430826","citation_count":125,"is_preprint":false},{"pmid":"10377280","id":"PMC_10377280","title":"The PML nuclear bodies: actors or extras?","date":"1999","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/10377280","citation_count":116,"is_preprint":false},{"pmid":"11704853","id":"PMC_11704853","title":"PML interaction with p53 and its role in apoptosis and replicative senescence.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11704853","citation_count":103,"is_preprint":false},{"pmid":"29416846","id":"PMC_29416846","title":"PML: Regulation and multifaceted function beyond tumor suppression.","date":"2018","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/29416846","citation_count":94,"is_preprint":false},{"pmid":"12934066","id":"PMC_12934066","title":"Body language: the function of PML nuclear bodies in apoptosis regulation.","date":"2003","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/12934066","citation_count":93,"is_preprint":false},{"pmid":"18504460","id":"PMC_18504460","title":"New insights into the role of PML in tumour suppression.","date":"2008","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18504460","citation_count":93,"is_preprint":false},{"pmid":"12917339","id":"PMC_12917339","title":"ZIP kinase triggers apoptosis from nuclear PML oncogenic domains.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12917339","citation_count":88,"is_preprint":false},{"pmid":"1310153","id":"PMC_1310153","title":"Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1310153","citation_count":86,"is_preprint":false},{"pmid":"28931625","id":"PMC_28931625","title":"PML is a ROS sensor activating p53 upon oxidative stress.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28931625","citation_count":86,"is_preprint":false},{"pmid":"21172801","id":"PMC_21172801","title":"PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/21172801","citation_count":86,"is_preprint":false},{"pmid":"22710964","id":"PMC_22710964","title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.","date":"2012","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22710964","citation_count":84,"is_preprint":false},{"pmid":"19808868","id":"PMC_19808868","title":"Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19808868","citation_count":79,"is_preprint":false},{"pmid":"25482067","id":"PMC_25482067","title":"PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.","date":"2014","source":"Nucleus (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25482067","citation_count":78,"is_preprint":false},{"pmid":"28521962","id":"PMC_28521962","title":"The functional roles of PML nuclear bodies in genome maintenance.","date":"2017","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/28521962","citation_count":73,"is_preprint":false},{"pmid":"18809579","id":"PMC_18809579","title":"PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18809579","citation_count":73,"is_preprint":false},{"pmid":"28691927","id":"PMC_28691927","title":"Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28691927","citation_count":68,"is_preprint":false},{"pmid":"18625722","id":"PMC_18625722","title":"Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18625722","citation_count":66,"is_preprint":false},{"pmid":"12759344","id":"PMC_12759344","title":"Physical and functional interactions between PML and MDM2.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12759344","citation_count":64,"is_preprint":false},{"pmid":"28143738","id":"PMC_28143738","title":"Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis.","date":"2017","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28143738","citation_count":56,"is_preprint":false},{"pmid":"20577263","id":"PMC_20577263","title":"SIRT1 stabilizes PML promoting its sumoylation.","date":"2010","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/20577263","citation_count":51,"is_preprint":false},{"pmid":"27553708","id":"PMC_27553708","title":"Stratification and therapeutic potential of PML in metastatic breast cancer.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27553708","citation_count":50,"is_preprint":false},{"pmid":"22274616","id":"PMC_22274616","title":"PML regulates PER2 nuclear localization and circadian function.","date":"2012","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22274616","citation_count":50,"is_preprint":false},{"pmid":"26566030","id":"PMC_26566030","title":"PML/TRIM19-Dependent Inhibition of Retroviral Reverse-Transcription by Daxx.","date":"2015","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/26566030","citation_count":49,"is_preprint":false},{"pmid":"10944585","id":"PMC_10944585","title":"The puzzling multiple lives of PML and its role in the genesis of cancer.","date":"2000","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10944585","citation_count":49,"is_preprint":false},{"pmid":"18508722","id":"PMC_18508722","title":"PML NBs (ND10) and Daxx: from nuclear structure to protein function.","date":"2008","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/18508722","citation_count":48,"is_preprint":false},{"pmid":"19273133","id":"PMC_19273133","title":"PML nuclear bodies as sites of epigenetic regulation.","date":"2009","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19273133","citation_count":47,"is_preprint":false},{"pmid":"32527650","id":"PMC_32527650","title":"PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy.","date":"2020","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32527650","citation_count":42,"is_preprint":false},{"pmid":"18413804","id":"PMC_18413804","title":"UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation.","date":"2008","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18413804","citation_count":42,"is_preprint":false},{"pmid":"8952164","id":"PMC_8952164","title":"PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia.","date":"1996","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/8952164","citation_count":41,"is_preprint":false},{"pmid":"21115099","id":"PMC_21115099","title":"PML positively regulates interferon gamma signaling.","date":"2010","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/21115099","citation_count":39,"is_preprint":false},{"pmid":"23847762","id":"PMC_23847762","title":"PML, SUMOylation, and Senescence.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23847762","citation_count":38,"is_preprint":false},{"pmid":"10699936","id":"PMC_10699936","title":"Lack of expression for the suppressor PML in human small cell lung carcinoma.","date":"2000","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10699936","citation_count":38,"is_preprint":false},{"pmid":"28740552","id":"PMC_28740552","title":"NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/28740552","citation_count":38,"is_preprint":false},{"pmid":"16891316","id":"PMC_16891316","title":"ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16891316","citation_count":38,"is_preprint":false},{"pmid":"17432977","id":"PMC_17432977","title":"Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.","date":"2007","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/17432977","citation_count":37,"is_preprint":false},{"pmid":"21998700","id":"PMC_21998700","title":"Functional connection between Rad51 and PML in homology-directed repair.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21998700","citation_count":36,"is_preprint":false},{"pmid":"26595813","id":"PMC_26595813","title":"PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26595813","citation_count":35,"is_preprint":false},{"pmid":"21217775","id":"PMC_21217775","title":"PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21217775","citation_count":35,"is_preprint":false},{"pmid":"17996922","id":"PMC_17996922","title":"Expression and localization of Werner syndrome protein is modulated by SIRT1 and PML.","date":"2007","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/17996922","citation_count":34,"is_preprint":false},{"pmid":"21501958","id":"PMC_21501958","title":"The nuclear bodies inside out: PML conquers the cytoplasm.","date":"2011","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21501958","citation_count":33,"is_preprint":false},{"pmid":"12506013","id":"PMC_12506013","title":"Opposing effects of PML and PML/RAR alpha on STAT3 activity.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12506013","citation_count":33,"is_preprint":false},{"pmid":"27162364","id":"PMC_27162364","title":"PML plays both inimical and beneficial roles in HSV-1 replication.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27162364","citation_count":33,"is_preprint":false},{"pmid":"22002537","id":"PMC_22002537","title":"Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22002537","citation_count":33,"is_preprint":false},{"pmid":"8986606","id":"PMC_8986606","title":"The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.","date":"1996","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/8986606","citation_count":33,"is_preprint":false},{"pmid":"25258343","id":"PMC_25258343","title":"Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25258343","citation_count":33,"is_preprint":false},{"pmid":"31439836","id":"PMC_31439836","title":"B1 oligomerization regulates PML nuclear body biogenesis and leukemogenesis.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31439836","citation_count":32,"is_preprint":false},{"pmid":"22935031","id":"PMC_22935031","title":"The role of PML ubiquitination in human malignancies.","date":"2012","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/22935031","citation_count":30,"is_preprint":false},{"pmid":"24861946","id":"PMC_24861946","title":"PML control of cytokine signaling.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24861946","citation_count":29,"is_preprint":false},{"pmid":"1337847","id":"PMC_1337847","title":"RARA and PML genes in acute promyelocytic leukemia.","date":"1992","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/1337847","citation_count":29,"is_preprint":false},{"pmid":"19273079","id":"PMC_19273079","title":"PML links aberrant cytokine signaling and oncogenic stress to cellular senescence.","date":"2009","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19273079","citation_count":28,"is_preprint":false},{"pmid":"29735542","id":"PMC_29735542","title":"PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29735542","citation_count":28,"is_preprint":false},{"pmid":"11007958","id":"PMC_11007958","title":"The promyelocytic (PML) nuclear compartment and transcription control.","date":"2000","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11007958","citation_count":28,"is_preprint":false},{"pmid":"27000403","id":"PMC_27000403","title":"The interferon-induced antiviral protein PML (TRIM19) promotes the restriction and transcriptional silencing of lentiviruses in a context-specific, isoform-specific fashion.","date":"2016","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/27000403","citation_count":27,"is_preprint":false},{"pmid":"28528440","id":"PMC_28528440","title":"The Human CMV IE1 Protein: An Offender of PML Nuclear Bodies.","date":"2017","source":"Advances in anatomy, embryology, and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28528440","citation_count":27,"is_preprint":false},{"pmid":"29535160","id":"PMC_29535160","title":"Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation.","date":"2018","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/29535160","citation_count":27,"is_preprint":false},{"pmid":"29926514","id":"PMC_29926514","title":"A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.","date":"2018","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29926514","citation_count":24,"is_preprint":false},{"pmid":"23563177","id":"PMC_23563177","title":"PML-mediated signaling and its role in cancer stem cells.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23563177","citation_count":23,"is_preprint":false},{"pmid":"35194189","id":"PMC_35194189","title":"Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL.","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35194189","citation_count":23,"is_preprint":false},{"pmid":"17172828","id":"PMC_17172828","title":"A cytoplasmic PML mutant inhibits p53 function.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17172828","citation_count":23,"is_preprint":false},{"pmid":"25092303","id":"PMC_25092303","title":"The PML domain of PML-RARα blocks senescence to promote leukemia.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25092303","citation_count":22,"is_preprint":false},{"pmid":"31416160","id":"PMC_31416160","title":"PML Bodies in Mitosis.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31416160","citation_count":21,"is_preprint":false},{"pmid":"36230470","id":"PMC_36230470","title":"Regulating the p53 Tumor Suppressor Network at PML Biomolecular Condensates.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36230470","citation_count":21,"is_preprint":false},{"pmid":"28555140","id":"PMC_28555140","title":"Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28555140","citation_count":21,"is_preprint":false},{"pmid":"9031108","id":"PMC_9031108","title":"The biologic function of PML and its role in acute promyelocytic leukemia.","date":"1996","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9031108","citation_count":20,"is_preprint":false},{"pmid":"21251247","id":"PMC_21251247","title":"Nogo-B regulates migration and contraction of airway smooth muscle cells by decreasing ARPC 2/3 and increasing MYL-9 expression.","date":"2011","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/21251247","citation_count":20,"is_preprint":false},{"pmid":"28332630","id":"PMC_28332630","title":"PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28332630","citation_count":20,"is_preprint":false},{"pmid":"30536958","id":"PMC_30536958","title":"PML/RARA inhibits expression of HSP90 and its target AKT.","date":"2018","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/30536958","citation_count":19,"is_preprint":false},{"pmid":"19273081","id":"PMC_19273081","title":"Perspectives in PML: a unifying framework for PML function.","date":"2009","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19273081","citation_count":19,"is_preprint":false},{"pmid":"28074026","id":"PMC_28074026","title":"Promyelocytic Leukemia Protein (PML) Controls Listeria monocytogenes Infection.","date":"2017","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/28074026","citation_count":19,"is_preprint":false},{"pmid":"32240679","id":"PMC_32240679","title":"Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32240679","citation_count":19,"is_preprint":false},{"pmid":"26703718","id":"PMC_26703718","title":"TRIM19/PML Restricts HIV Infection in a Cell Type-Dependent Manner.","date":"2015","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/26703718","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42577,"output_tokens":9862,"usd":0.13783,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20312,"output_tokens":4756,"usd":0.11023,"stage2_stop_reason":"end_turn"},"total_usd":0.24806,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"Arsenic trioxide induces PML SUMOylation, which triggers Lys48-linked polyubiquitination of PML and recruits RNF4 (the human orthologue of the yeast SUMO-dependent E3 ubiquitin ligase) to PML nuclear bodies, leading to proteasome-dependent degradation of PML and PML-RARα. SUMOylated PML also recruits ubiquitin and proteasomes onto PML nuclear bodies. A dominant-negative RNF4 impairs arsenic-induced differentiation, directly implicating PML-RARα catabolism in the therapeutic response.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative RNF4 expression, SUMOylation mutant analysis, ubiquitination assays, cell differentiation assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, dominant-negative rescue, SUMOylation mutant, and functional differentiation readout; widely replicated concept\",\n      \"pmids\": [\"18408733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PML nuclear bodies coordinate PTEN localization by opposing the deubiquitylating enzyme HAUSP/USP7 through a mechanism involving the adaptor protein DAXX. PML opposes HAUSP-mediated deubiquitylation of PTEN, which is required for PTEN nuclear entry. This PML-DAXX-HAUSP network controls PTEN subcellular trafficking and is disrupted by the PML-RARα oncoprotein.\",\n      \"method\": \"Co-immunoprecipitation, knockdown/knockout studies, ubiquitylation assays, nuclear/cytoplasmic fractionation, rescue experiments with ATRA/arsenic trioxide\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, multiple orthogonal methods (fractionation, KO cells, drug rescue), single lab with rigorous controls\",\n      \"pmids\": [\"18716620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Cytoplasmic PML isoforms are essential modulators of TGF-β signaling. Cytoplasmic PML physically interacts with Smad2/3 and SARA (Smad anchor for receptor activation) and is required for Smad2/3 phosphorylation, nuclear translocation, SARA association, and accumulation of SARA and TGF-β receptor in early endosomes. PML-null primary cells are resistant to TGF-β-dependent growth arrest, senescence, and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, Pml-null primary cell phenotyping, Smad2/3 phosphorylation assays, endosomal fractionation, cytoplasmic PML expression rescue\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, KO cells with defined phenotype, multiple orthogonal methods, published in high-impact journal\",\n      \"pmids\": [\"15356634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PML inhibits HIF-1α synthesis under hypoxic conditions by repressing mTOR. PML physically interacts with mTOR and negatively regulates mTOR association with the small GTPase Rheb by promoting mTOR nuclear accumulation. Pml−/− cells and tumours display higher sensitivity to rapamycin and lack of PML inversely correlates with phosphorylation of ribosomal protein S6.\",\n      \"method\": \"Co-immunoprecipitation (PML-mTOR), Pml-null cell/tumour analysis, rapamycin sensitivity assays, subcellular fractionation showing mTOR nuclear accumulation, in vivo tumour models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, KO model, multiple orthogonal assays (fractionation, rapamycin sensitivity, S6 phosphorylation), in vivo validation\",\n      \"pmids\": [\"16915281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PML physically interacts with p53 both in vitro and in vivo, co-localizes with p53 in PML nuclear bodies, and acts as a transcriptional co-activator for p53. PML-dependent p53-DNA binding activity, p53 transcriptional activation, and induction of p53 target genes (Bax, p21) upon gamma-irradiation are all impaired in Pml−/− primary cells.\",\n      \"method\": \"In vitro GST pulldown, co-immunoprecipitation in vivo, co-localization by immunofluorescence, Pml−/− cell apoptosis and transcription assays, gamma-irradiation\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro pulldown plus in vivo Co-IP, KO cells with functional transcription and apoptosis readouts, replicated across subsequent studies\",\n      \"pmids\": [\"11025664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PML function is essential for the tumor-growth-suppressive activity of retinoic acid (RA) and for RA-induced terminal myeloid differentiation. PML is required for RA-dependent transactivation of the p21WAF1/CIP1 gene, placing PML as a critical component of the RA signaling pathway.\",\n      \"method\": \"Homologous recombination knockout of murine PML, hematopoietic differentiation assays, RA-dependent p21 transactivation assays, tumorigenesis assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined pathway placement, RA transactivation assay, in vivo tumorigenesis model\",\n      \"pmids\": [\"9488655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PML interacts with multiple corepressors (c-Ski, N-CoR, mSin3A) and histone deacetylase 1, and this interaction is required for transcriptional repression mediated by the tumor suppressor Mad. PML-RARα, which has two corepressor-interacting sites, inhibits Mad-mediated repression, suggesting aberrant binding to corepressor complexes contributes to leukemogenesis.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional reporter assays, domain mapping\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with multiple corepressors, functional transcription repression assay, single lab\",\n      \"pmids\": [\"11430826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PML colocalizes with the non-phosphorylated fraction of the retinoblastoma protein (pRB) in nuclear bodies. Both PML and PML-RARα form complexes with the non-phosphorylated form of pRB in vivo and interact with the pRB pocket region. The B boxes and C-terminal region of PML are essential for stable complex formation. PML abolishes glucocorticoid receptor-regulated transcription activation by pRB.\",\n      \"method\": \"Co-immunoprecipitation, co-localization immunofluorescence, domain deletion mutant analysis, transcriptional reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, domain mapping, functional transcription assay, single lab\",\n      \"pmids\": [\"9448006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The DNA damage checkpoint kinase hCds1/Chk2 mediates gamma irradiation-induced apoptosis in a p53-independent manner through an ATM-hCds1/Chk2-PML pathway. PML functions downstream of ATM-hCds1/Chk2 in this pathway, defining PML's role in the p53-independent apoptotic arm of the DNA damage response.\",\n      \"method\": \"Genetic epistasis in cell lines, gamma irradiation apoptosis assays, kinase activity assays, PML-null cell studies\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis analysis with defined pathway, PML-null cells, single lab\",\n      \"pmids\": [\"12402044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PML physically interacts with MDM2 in vivo and in vitro through two separate regions: PML residues 300–633 interact with the MDM2 acidic domain, and PML residues 1–200 (RING/B-box region) interact with the MDM2 C-terminal RING domain. MDM2 coexpression redistributes PML from nucleus to cytoplasm via interaction with the PML N-terminus and MDM2 RING domain. MDM2 inhibits PML-stimulated transcriptional activation of CBP. PML SUMOylation at K160 negatively regulates PML-MDM2 binding.\",\n      \"method\": \"Co-immunoprecipitation in vivo, GST pulldown in vitro, domain deletion mutants, subcellular fractionation, transcriptional reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro pulldown plus in vivo Co-IP, domain mapping, functional transcription assay, single lab\",\n      \"pmids\": [\"12759344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated ubiquitin-proteasomal degradation. PML forms a complex containing Fbx3, Skp1, and Cullin1 (SCFFbx3 ubiquitin ligase). PML inhibits degradation of HIPK2 and p300 without inhibiting their ubiquitination, and PML/Fbx3/HIPK2 synergistically activate p53-induced transcription. PML-RARα instead promotes HIPK2 degradation.\",\n      \"method\": \"PML complex purification and mass spectrometry identification, co-immunoprecipitation, ubiquitination assays, transcriptional reporter assays, proteasome inhibitor studies\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complex purification by MS, Co-IP, functional transcription assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"18809579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HDAC7 promotes PML SUMOylation essential for PML nuclear body formation. HDAC7 associates with the SUMO E2 ligase Ubc9 and stimulates PML SUMOylation in vitro, acting with SUMO E3 ligase-like activity. HDAC7 knockdown reduces PML nuclear body size and number and inhibits TNF-α-induced PML SUMOylation in HUVECs.\",\n      \"method\": \"HDAC7 knockdown (siRNA), in vitro SUMOylation assay, co-immunoprecipitation, immunofluorescence of PML bodies\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro SUMOylation assay, Co-IP, KD with phenotypic readout, single lab\",\n      \"pmids\": [\"18625722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PML is critical for proper localization of all other ND10/PML-body-associated proteins. Introducing PML into PML−/− cells recruits ND10-associated proteins (including Daxx, Sp100) into de novo formed ND10 bodies. Increased SUMO-1 modification of PML segregates Daxx from condensed chromatin to ND10, demonstrating that SUMO-1 modification of PML controls recruitment of partner proteins.\",\n      \"method\": \"Transient transfection in PML−/− cells, cell fusion experiments, immunofluorescence, SUMO-1 overexpression\",\n      \"journal\": \"Journal of structural biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PML reconstitution in null cells, multiple partner proteins assessed, single lab\",\n      \"pmids\": [\"10806078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PML and Sp100 are conjugated to SUMO-1 during interphase but become de-conjugated during mitosis. A mitosis-specific PML isoform of distinct electrophoretic mobility appears that is stabilized by phosphatase inhibitors, indicating phosphorylation is an important modifier of PML during the cell cycle. Treatment with phosphatase inhibitors in interphase cells induces PML isoforms resembling the mitotic form and causes structural changes in ND10.\",\n      \"method\": \"Cell cycle synchronization, immunoblotting for SUMO-1-conjugated PML, phosphatase inhibitor treatment, immunofluorescence of PML bodies\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical cell-cycle analysis, pharmacological modulation, single lab with multiple conditions\",\n      \"pmids\": [\"10574707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PML nuclear body core is a dense, protein-based structure (~250 nm diameter) that does not contain detectable nucleic acid (no RNA or chromatin). Newly synthesized RNA is associated with the periphery of PML nuclear bodies, not within the protein core. These bodies are not sites of transcription.\",\n      \"method\": \"Electron spectroscopic imaging (ESI) analytical transmission electron microscopy, 5-bromouridine RNA labeling\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative structural method (ESI-TEM) with rigorous compositional analysis, directly falsified prior RNA-accumulation model\",\n      \"pmids\": [\"10648561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PML and YAP physically interact through PML's PVPVY motif and YAP's WW domain. PML-mediated SUMOylation stabilizes YAP. PML is a direct transcriptional target of p73/YAP, forming a proapoptotic autoregulatory feedback loop. Akt/PKB kinase negatively controls PML transcriptional activation by p73/YAP.\",\n      \"method\": \"Co-immunoprecipitation, domain mutant analysis (PVPVY/WW), SUMOylation assays, transcriptional reporter assays, Akt inhibitor studies\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping, SUMOylation assay, functional transcription readout, single lab\",\n      \"pmids\": [\"19111660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PML forms a complex with STAT3 through its B-box and C-terminal regions in vitro and in vivo, inhibiting STAT3 DNA-binding activity. PML-RARα dissociates PML from STAT3 and restores STAT3 activity. In cells dependent on gp130/STAT3-mediated growth, PML abrogates proliferation while PML-RARα enhances it.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, luciferase transcription assays, EMSA for STAT3 DNA binding, Ba/F3 cell growth assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro pulldown, in vivo Co-IP, EMSA, functional cell growth assay, single lab\",\n      \"pmids\": [\"12506013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ZIP kinase (ZIPK) is present in PML nuclear bodies (PODs) and colocalizes with and binds to proapoptotic protein Daxx. Arsenic trioxide and IFN-γ increase the association of ZIPK with PODs. Kinase-inactive ZIPK has diffuse nuclear localization and prevents Daxx association with PODs, indicating ZIPK recruits Daxx via its catalytic activity. ZIPK also binds and phosphorylates Par-4; siRNA knockdown of ZIPK, Daxx, or Par-4 decreases caspase activation and apoptosis induced by arsenic/IFN-γ.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, kinase-dead mutant analysis, siRNA knockdown, caspase activity assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, kinase-dead mutant, siRNA KD with functional apoptosis readout, single lab\",\n      \"pmids\": [\"12917339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PML isoforms I and II partially restore restriction of ICP0-null mutant HSV-1 replication in PML-depleted cells. The antiviral activity of PML isoform I requires its SUMO modification, its SUMO interaction motif (SIM), and each element of its TRIM domain. Deletion of the SIM motif from PML isoform I increases colocalization with other major ND10 components.\",\n      \"method\": \"Individual PML isoform expression in PML-depleted cells, viral plaque assays, SUMO modification site mutagenesis, SIM deletion mutants, immunofluorescence\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific rescue, domain mutants, functional viral replication assay, single lab\",\n      \"pmids\": [\"21172801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SIRT1 stabilizes PML protein and stimulates PML SUMOylation in vitro and in vivo in a deacetylase-independent manner. SIRT1 knockdown reduces PML protein levels, PML nuclear body size and number. SIRT1 absence reduces the apoptotic response to VSV infection and favors PML-sensitive virus replication.\",\n      \"method\": \"In vitro SUMOylation assay, SIRT1 knockdown (shRNA/siRNA), SIRT1 knockout MEFs, immunofluorescence of PML bodies, viral replication assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro SUMOylation assay, KO cells, KD with functional readouts, single lab\",\n      \"pmids\": [\"20577263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PML induces a permanent cell cycle exit and activates p53 and senescence by recruiting E2F transcription factors (bound to their promoters) and Rb proteins to PML nuclear bodies enriched in heterochromatin proteins and protein phosphatase 1α. Blocking Rb family function or adding back E2Fs rescues E2F-dependent gene expression and proliferation, inhibiting the senescent phenotype.\",\n      \"method\": \"Immunoprecipitation, immunofluorescence, chromatin immunoprecipitation (ChIP), Rb functional blockade, E2F rescue experiments, cell proliferation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, Co-IP, rescue experiments, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"21205865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PML protein physically interacts with PER2 and is expressed in a circadian manner in the suprachiasmatic nucleus (SCN). Loss of PML disrupts expression of clock regulators (Per2, Per1, Cry1, Bmal1, Npas2), and in Pml−/− cells PER2 distribution is primarily perinuclear/cytoplasmic rather than nuclear. PML is acetylated at K487, and its deacetylation by SIRT1 promotes PML control of PER2 nuclear localization. In Pml−/− mice, circadian period shows reduced precision and stability.\",\n      \"method\": \"Co-immunoprecipitation (PML-PER2), Pml−/− mouse circadian phenotyping, immunofluorescence/subcellular fractionation of PER2, acetylation site mutagenesis (K487), SIRT1 deacetylation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, KO mouse phenotype, acetylation site mutagenesis, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22274616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PML/TRIM19 inhibits retroviral (HIV-1) reverse transcription indirectly through stabilization of Daxx. In the presence of PML, cytoplasmic Daxx is found in the vicinity of incoming HIV-1 capsids and inhibits reverse transcription. HIV-1 infection triggers formation of PML cytoplasmic bodies within 30 min, peaking at ~2 h post-infection. PML re-localization is blocked by reverse-transcription inhibitors.\",\n      \"method\": \"PML knockdown (siRNA), quantitative RT-PCR of HIV cDNA intermediates, immunofluorescence of PML cytoplasmic bodies, reverse-transcription inhibitor treatment, Daxx depletion experiments\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with functional viral replication assay, imaging, pharmacological inhibition, single lab\",\n      \"pmids\": [\"26566030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PML is functionally connected to the homologous recombination (HR) repair machinery. PML depletion abrogates Rad51, Mre11, BRCA1, and RPA foci following DNA damage. PML associates with Rad51 following LT expression or external DNA damage. PML-depleted cells fail to generate ssDNA foci or activate Chk1 upon gamma-irradiation, indicating PML is required for DSB processing. PML is also required for HR-mediated repair as measured by a direct HR assay.\",\n      \"method\": \"PML knockdown (siRNA), immunofluorescence for DNA repair foci, Co-immunoprecipitation (PML-Rad51), HR reporter assay, BrdU incorporation (ssDNA detection), Chk1 phosphorylation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, multiple foci assays, functional HR assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21998700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PML acts as a reactive oxygen species (ROS) sensor. Pml−/− cells accumulate ROS, whereas PML expression decreases ROS levels. Pml−/− animals fail to properly activate oxidative stress-responsive p53 targets, while the NRF2 response is amplified. In an oxidative stress-prone background, Pml−/− animals display a longevity phenotype reflecting decreased basal p53 activation. PML couples ROS sensing to p53 responses through NB biogenesis.\",\n      \"method\": \"Pml−/− mouse models, ROS measurement assays, p53 target gene induction assays, acetaminophen hepatotoxicity model, fasting-induced steatosis model, glutathione depletion experiment\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse model with multiple in vivo stress paradigms, molecular target gene readouts, single lab\",\n      \"pmids\": [\"28931625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PML RBCC domain undergoes sequential oligomerization (monomer → dimer → tetramer → N-mer) mediated by B1-box interfaces (W157, F158, SD1). Crystal structure of PML B1-box at 2.0 Å resolution and SAXS characterization define these interfaces. B1 interface mutations abolish PML SUMOylation and nuclear body biogenesis in HeLaPml−/− cells. In vivo, PML-RARα F158E mutation (disrupting B1 oligomerization) precludes leukemogenesis in transgenic mice.\",\n      \"method\": \"Crystal structure (2.0 Å), SAXS, gel filtration, ultracentrifugation, B1 interface mutagenesis, PML nuclear body reconstitution in HeLaPml−/− cells, transgenic mouse leukemogenesis model, single-cell RNA sequencing\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mutagenesis, SAXS, in vitro biochemistry, in vivo transgenic mouse validation, multiple orthogonal methods\",\n      \"pmids\": [\"31439836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"WDR4-containing CRL4WDR4 ubiquitin ligase mediates PML ubiquitination and degradation. This pathway is hyperactivated in lung cancer. The WDR4/PML axis induces CD73, uPAR, and SAA2 to elicit paracrine effects promoting migration, invasion, and metastasis. In vivo, this axis elevates intratumoral Tregs and M2-like macrophages and reduces CD8+ T cells.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, WDR4 knockdown/overexpression, xenograft and genetically engineered mouse models, CD73 blockade rescue\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, in vivo mouse models, rescue experiment, single lab\",\n      \"pmids\": [\"28691927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Overexpression of nuclear PML isoforms (I–VI) in human cells increases IFN-γ-induced STAT1 phosphorylation, enhances STAT1 DNA binding, activates IFN-stimulated genes, and increases their protein products. These effects require PML nuclear localization, PML SUMOylation, and the RING finger domain. Conversely, PML knockdown or PML−/− MEFs show decreased IFN-γ-induced STAT1 phosphorylation and STAT1 DNA-binding activity.\",\n      \"method\": \"PML isoform overexpression, PML siRNA knockdown, PML−/− MEF analysis, STAT1 phosphorylation assays, EMSA for STAT1 DNA binding, ISG expression assays, SUMOylation mutant analysis\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific effects, KO cells, domain mutants, EMSA, single lab with multiple methods\",\n      \"pmids\": [\"21115099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PML physically binds TET2 via its C-terminal domain and recruits TET2 to PML-positive nuclear bodies, promoting 5-hydroxymethylcytosine (5hmC) formation in response to chemotherapeutic agents. PML-RARA (missing the PML C-terminal domain) disrupts this interaction. Knockout of PML abolishes doxorubicin-promoted DNA modification.\",\n      \"method\": \"SILAC immunoprecipitation-mass spectrometry, co-immunoprecipitation, PML KO cells, 5hmC quantification, domain-deletion mutant analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-based interactome identification, Co-IP confirmation, KO cells with functional 5hmC readout, single lab\",\n      \"pmids\": [\"29735542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PML undergoes oxidation-mediated multimerization and de-SUMOylation in response to Listeria monocytogenes infection via the pore-forming toxin listeriolysin O (LLO). This de-SUMOylation is sensed as a danger signal leading to restriction of bacterial intracellular multiplication. Specific induction of PML de-SUMOylation phenocopies the LLO-induced antibacterial response.\",\n      \"method\": \"PML oxidation/multimerization assays, SUMOylation immunoblotting, LLO-deficient Listeria mutant comparison, PML de-SUMOylation induction, transcriptomic and proteomic microarrays, Pml−/− cell infection assays\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical modification assays, bacterial mutant controls, pharmacological de-SUMOylation, KO cells, single lab\",\n      \"pmids\": [\"28074026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IFN-α treatment increases global cellular SUMOylation in a PML-dependent manner. This effect is orchestrated specifically by PML isoforms III and IV. IFN-α induces PML-dependent transfer of the SUMO E2 enzyme UBC9 to the nuclear matrix where it colocalizes with PML in nuclear bodies and enhances global SUMOylation.\",\n      \"method\": \"Large-scale SUMO proteomics (mass spectrometry), individual PML isoform expression in PML-negative cells, UBC9 nuclear matrix fractionation, immunofluorescence co-localization\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics, isoform-specific rescue, fractionation, Co-localization, single lab\",\n      \"pmids\": [\"29535160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PML physically interacts with TBX2 (a T-box transcription factor) and negatively regulates TBX2 expression. Recruitment of PML to the TBX2 promoter depends on a functional p130/E2F4 repressor complex, implementing transcriptionally inactive chromatin at the TBX2 promoter. TBX2 depletion triggers PML pro-senescence functions; elevated TBX2 antagonizes PML pro-senescence function through direct protein-protein interaction.\",\n      \"method\": \"ChIP, gene expression profiling, promoter reporter assay, co-immunoprecipitation, TBX2 knockdown and overexpression, senescence assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, Co-IP, functional senescence assays, multiple methods, single lab\",\n      \"pmids\": [\"22002537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The MYL/PML-RARα fusion protein encoded by the t(15;17) translocation of APL includes RAR-α DNA- and retinoid-binding regions but lacks the RAR-α N-terminal A/B transactivation domain. The fusion protein acts as a retinoid-inducible transcription factor with ligand-independent repressor and ligand-dependent activator functions, and has ~10-fold greater affinity for RA than RARα alone.\",\n      \"method\": \"cDNA cloning and sequencing, retinoid-binding assays, transactivation reporter assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro binding assay, transactivation assay, molecular characterization, single lab\",\n      \"pmids\": [\"1650447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PML overexpression induces rapid cell death independent of de novo transcription, caspase-3 activation, or cell cycling. BAX and p27KIP1 are novel PML nuclear body-associated proteins recruited by PML. Arsenic enhances targeting of PML, BAX, and p27KIP1 to nuclear bodies and synergizes with PML and IFN to induce cell death. Caspase inhibitors (zVAD) accelerate PML-induced death.\",\n      \"method\": \"PML overexpression in multiple cell lines, immunofluorescence for BAX/p27KIP1 localization at NBs, caspase inhibitor treatment, arsenic trioxide treatment, cell death assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence, pharmacological rescue, single lab\",\n      \"pmids\": [\"9806544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PML/RARα is neddylated in its RARα moiety; this neddylation enhances DNA-binding ability of PML/RARα and impedes phase separation of the PML moiety, disrupting PML nuclear body assembly. Deneddylation of PML/RARα restores its phase separation to reconstruct functional PML nuclear bodies and activates RARα signaling, suppressing leukemogenesis. Pharmacological neddylation inhibition by MLN4924 eradicates APL cells in vitro and in vivo.\",\n      \"method\": \"Neddylation site identification, DNA-binding assays, phase separation assays, PML NB reconstitution, MLN4924 treatment in vitro and in APL mouse models\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — neddylation assays, phase separation assay, in vivo APL model, pharmacological rescue, single lab\",\n      \"pmids\": [\"35194189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"UBE1L (ubiquitin-activating enzyme E1-like) induces ISG15 conjugation (ISG15ylation) of the PML domain of PML/RARα, causing its repression and degradation via the proteasome. This is mechanistically distinct from RA-induced RARα-domain targeting. USP18/UBP43 (the ISG15 deconjugase) opposes UBE1L-dependent (but not RA-dependent) PML/RARα degradation.\",\n      \"method\": \"Domain-specific transfection assays, ISG15ylation assays, proteasome inhibitor studies, USP18 rescue experiments\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-specific ISG15ylation assay, proteasome inhibitor, specific deconjugase rescue, single lab\",\n      \"pmids\": [\"18413804\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PML is the essential scaffold of PML nuclear bodies (NBs) — protein-based subnuclear organelles assembled through sequential B1-box-mediated oligomerization — where it functions as a SUMO E3 ligase platform that concentrates partner proteins (including p53, pRB, STAT3, Smad2/3, TET2, Daxx, Rad51, HIPK2, p300, and many others) to regulate their post-translational modification (SUMOylation, acetylation, ubiquitination), stability, localization, and activity; PML also acts in the cytoplasm as a TGF-β signal transducer by scaffolding Smad2/3-SARA complexes at early endosomes, suppresses mTOR by promoting its nuclear sequestration away from Rheb, senses reactive oxygen species to couple oxidative stress to p53 activation, and undergoes SUMO-triggered RNF4-mediated polyubiquitination and proteasomal degradation in response to arsenic trioxide, which underpins the therapeutic clearance of PML-RARα in acute promyelocytic leukemia.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PML is the essential scaffold of PML nuclear bodies (ND10), subnuclear protein-based structures that concentrate partner proteins to control their post-translational modification, stability, and localization; introducing PML into PML-null cells recruits ND10-associated proteins such as Daxx and Sp100, and increased SUMO-1 modification of PML drives this recruitment [#12]. Body biogenesis depends on sequential B1-box-mediated oligomerization of the PML RBCC domain (monomer→dimer→tetramer→N-mer), and B1-interface mutations abolish PML SUMOylation and nuclear-body formation [#25]; the body core is a dense protein structure that excludes nucleic acid and is not a site of transcription [#14]. PML SUMOylation is the central regulatory switch governing partner recruitment, and is stimulated by accessory factors including HDAC7 and SIRT1, both of which control PML body size and number [#11, #19]. Through these bodies PML potentiates p53 function, acting as a p53 transcriptional co-activator required for p53 target induction after gamma-irradiation [#4] and coupling reactive oxygen species sensing to p53 activation, with Pml-null animals failing to mount oxidative-stress-responsive p53 programs [#24]; it likewise enforces senescence by sequestering E2F/Rb complexes at heterochromatin-enriched bodies [#20] and contributes to homologous recombination repair by enabling Rad51, Mre11, BRCA1, and RPA focus formation and DSB processing [#23]. PML also functions outside the body and nucleus: cytoplasmic PML scaffolds Smad2/3-SARA complexes at early endosomes to transduce TGF-\\u03b2 signaling [#2], represses mTOR by promoting its nuclear sequestration away from Rheb [#3], and supports antiviral and antibacterial restriction through Daxx stabilization and oxidation-triggered de-SUMOylation [#22, #29]. In acute promyelocytic leukemia the t(15;17) PML-RAR\\u03b1 fusion retains RAR\\u03b1 DNA- and retinoid-binding regions while losing the RAR\\u03b1 transactivation domain [#32]; arsenic trioxide induces PML SUMOylation that triggers RNF4-dependent K48 polyubiquitination and proteasomal degradation of PML and PML-RAR\\u03b1, underpinning the therapeutic response, and PML function is required for retinoic-acid-induced differentiation and tumor suppression [#0, #5].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Defining the molecular nature of the APL fusion oncoprotein established that PML-RAR\\u03b1 is an aberrant retinoid receptor, framing PML's relevance to leukemia.\",\n      \"evidence\": \"cDNA cloning, retinoid-binding and transactivation assays of the t(15;17) fusion\",\n      \"pmids\": [\"1650447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not address normal PML function\", \"No structural mechanism for how the fusion subverts PML bodies\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Knockout of PML placed it as an essential effector of retinoic-acid-induced differentiation and tumor suppression, establishing physiological function beyond the fusion.\",\n      \"evidence\": \"Murine PML knockout, myeloid differentiation, RA-dependent p21 transactivation and tumorigenesis assays\",\n      \"pmids\": [\"9488655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which PML enables RA transactivation not resolved\", \"Did not establish the body-level mechanism\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Reconstitution in PML-null cells showed PML is the organizer that recruits all other ND10 components, defining its scaffold role and the SUMO-dependence of partner recruitment.\",\n      \"evidence\": \"Transfection/cell-fusion in PML-/- cells, immunofluorescence, SUMO-1 overexpression\",\n      \"pmids\": [\"10806078\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SUMO E3 machinery for PML not identified here\", \"Quantitative oligomerization mechanism unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Structural imaging established that PML body cores are protein-based and nucleic-acid-free, falsifying the prior model that bodies are transcription/RNA-accumulation sites.\",\n      \"evidence\": \"Electron spectroscopic imaging and 5-bromouridine RNA labeling\",\n      \"pmids\": [\"10648561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular assembly principle of the core\", \"Function of peripheral RNA association left open\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that PML co-activates p53 connected the bodies to a tumor-suppressor transcriptional program engaged after DNA damage.\",\n      \"evidence\": \"GST pulldown, in vivo Co-IP, PML-/- cell transcription and apoptosis assays after gamma-irradiation\",\n      \"pmids\": [\"11025664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether co-activation requires SUMO-dependent recruitment not shown\", \"Direct enzymatic role on p53 not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"PML was placed in a p53-independent DNA-damage apoptotic arm and shown to restrain STAT3, broadening its role to checkpoint signaling and cytokine response.\",\n      \"evidence\": \"ATM-Chk2 epistasis with PML-null cells; PML-STAT3 Co-IP, EMSA, Ba/F3 growth assays\",\n      \"pmids\": [\"12402044\", \"12506013\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link between Chk2 and PML not resolved\", \"How PML body localization gates STAT3 inhibition unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of a cytoplasmic PML pool scaffolding Smad2/3-SARA at endosomes established a non-nuclear signal-transduction function in TGF-\\u03b2 responses.\",\n      \"evidence\": \"Co-IP, Pml-null primary cell phenotyping, endosomal fractionation, cytoplasmic PML rescue\",\n      \"pmids\": [\"15356634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of nuclear vs cytoplasmic PML partitioning not defined\", \"Structural basis of Smad/SARA scaffolding unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"PML was shown to suppress mTOR by promoting its nuclear sequestration away from Rheb, linking the bodies to translational/hypoxic control.\",\n      \"evidence\": \"PML-mTOR Co-IP, Pml-null tumors, rapamycin sensitivity and S6 phosphorylation, in vivo tumor models\",\n      \"pmids\": [\"16915281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PML physically retains mTOR in the nucleus not detailed\", \"Relationship to NB SUMOylation switch unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Arsenic-induced PML SUMOylation was shown to recruit RNF4 and drive K48 polyubiquitination and proteasomal degradation of PML/PML-RAR\\u03b1, providing the molecular basis for APL therapy.\",\n      \"evidence\": \"Reciprocal Co-IP, dominant-negative RNF4, SUMO-site mutants, ubiquitination and differentiation assays\",\n      \"pmids\": [\"18408733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry/site specificity of the SUMO-ubiquitin handoff not fully mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Multiple 2008 studies expanded PML's modification-control logic: it gates PTEN nuclear trafficking via DAXX/HAUSP, protects HIPK2/p300 from SCFFbx3 degradation, and depends on HDAC7 for body-forming SUMOylation.\",\n      \"evidence\": \"Co-IP, ubiquitylation assays, fractionation, MS-based complex purification, in vitro SUMOylation, knockdowns\",\n      \"pmids\": [\"18716620\", \"18809579\", \"18625722\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each interaction characterized in single labs\", \"How a single scaffold coordinates so many distinct modification outcomes unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"PML was integrated into homologous-recombination repair and senescence enforcement, showing the bodies physically organize repair factors and E2F/Rb-driven cell-cycle exit.\",\n      \"evidence\": \"PML knockdown with Rad51/Mre11/BRCA1/RPA foci and HR reporter assays; ChIP/Co-IP of E2F-Rb recruitment with senescence rescue\",\n      \"pmids\": [\"21998700\", \"21205865\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PML acts directly on repair complexes or via sequestration unclear\", \"Causal order of body assembly vs senescence entry not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Structural and mutagenesis work defined the B1-box oligomerization interfaces required for SUMOylation and body biogenesis, and showed disrupting them blocks PML-RAR\\u03b1 leukemogenesis in vivo.\",\n      \"evidence\": \"2.0 \\u00c5 crystal structure, SAXS, B1-interface mutagenesis, NB reconstitution in HeLaPML-/-, transgenic mouse model\",\n      \"pmids\": [\"31439836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How oligomerization couples to the SUMO E2/E3 reaction mechanistically not fully defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Neddylation of the RAR\\u03b1 moiety was shown to impede PML phase separation and body assembly, with deneddylation (MLN4924) restoring functional bodies and suppressing leukemia, adding a phase-behavior layer to APL biology.\",\n      \"evidence\": \"Neddylation site mapping, phase separation and DNA-binding assays, NB reconstitution, MLN4924 in APL mouse models\",\n      \"pmids\": [\"35194189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In-cell evidence for endogenous PML phase separation limited\", \"Single-lab characterization\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many PML isoforms and the SUMOylation/oligomerization/phase-separation switches are integrated to select among the protein's diverse outputs (p53 co-activation, mTOR suppression, TGF-\\u03b2 transduction, repair, immune restriction) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking isoform identity to specific functional output\", \"Mechanism that partitions nuclear vs cytoplasmic PML pools undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 11, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 16, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 10, 1]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [24, 29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12, 14, 25]},\n      {\"term_id\": \"GO:0043226\", \"supporting_discovery_ids\": [12, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 22]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 32, 34]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 10, 30]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18, 22, 27, 29]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [23, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 33]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [24, 20]}\n    ],\n    \"complexes\": [\n      \"PML nuclear body (ND10)\",\n      \"SCF(Fbx3) ubiquitin ligase complex\",\n      \"Smad2/3-SARA endosomal complex\"\n    ],\n    \"partners\": [\n      \"p53\",\n      \"Daxx\",\n      \"RNF4\",\n      \"mTOR\",\n      \"Smad2/3\",\n      \"Rad51\",\n      \"TET2\",\n      \"STAT3\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}